Across a range of genetically engineered, patient-derived and orthoptic NSCLC models, [18F]FSPG retention increased in tumours with NRF2 activation compared to those with a normal-functioning NRF2/KEAP1 axis. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.